Every published Top AI Stories item tagged with Health Care & Social Assistance, newest first.
The AI image company Midjourney unveiled a medical division and its first hardware: an "Ultrasonic CT" scanner that uses 500,000 transducers and no radiation to image the whole body in about 60 seconds, reconstructing the scan with AI. Midjourney licensed Butterfly Network's ultrasound-on-chip technology and plans to debut the device in a San Francisco "spa" in late 2027, aiming for 50,000 machines worldwide by 2031.
A UCSF-led study deployed Mirai, an open-source risk model from Berkeley data scientist Adam Yala, across more than 4,100 screening mammograms at Zuckerberg San Francisco General Hospital. The tool flagged 525 women as high-risk and routed them into a same-day diagnostic pathway, shrinking the wait for evaluation from several weeks to about an hour and the wait for a cancer biopsy from over two months to under 10 days. Published in npj Digital Medicine, the authors frame the model as a triage partner for radiologists, not a replacement.
GE HealthCare won FDA clearance for MIM Contour ProtégéAI+ 2.0, software that automatically outlines tumors and healthy organs on CT and MR scans — one of the most time-consuming steps in planning radiation therapy. By handling the contouring with minimal input, it frees oncology teams to spend more time tailoring each patient's treatment. The clearance also includes a change-control plan that lets GE push future updates to new body regions faster, a sign regulators are adapting to clinical AI that keeps improving after approval.
University of Cambridge researchers began human trials of what they call the first vaccine whose central component was designed entirely by AI. The shot targets the whole Sarbeco coronavirus family — including Covid-19, SARS, and related bat viruses — in hopes of guarding against outbreaks that have not yet emerged. An early 39-person trial tested safety; a roughly 200-person study will gauge immune response. The team is already applying the same AI design approach to influenza and Ebola vaccines.
OpenAI announced its Rosalind Biodefense Program on Friday, opening GPT-Rosalind — a frontier model fine-tuned for life-sciences work — to select US government agencies, allied nations, and a vetted set of private developers. Named applications span epidemiological modeling, early detection, screening, preparedness, non-pharmaceutical interventions, and medical countermeasure development. OpenAI says it briefed the White House and federal public-health agencies on its approach, though it has not yet published red-team or misuse-prevention details for the dual-use model.
Anthropic announced a four-year, $200 million commitment to the Gates Foundation, structured as a mix of cash grants, Claude usage credits, and technical support from its Beneficial Deployments team. Focus areas span global health (polio, HPV, and preeclampsia and eclampsia among named disease targets), life sciences, education, and economic mobility, with regional emphasis on sub-Saharan Africa, India, and other low- and middle-income countries. Launch partners include the Institute for Disease Modeling and the Global AI for Learning Alliance. It is the largest single philanthropic commitment from a frontier lab to date and a meaningful structural signal that Anthropic intends to be measured by social-impact deployments alongside its commercial book.
CMS launched ACCESS (Advancing Chronic Care with Effective, Scalable Solutions), a 10-year initiative starting July 5 with 150 participating organizations and outcome-based payments that, for the first time, reimburse organizations for AI agents monitoring patients between visits, coordinating referrals, and managing medication adherence across six conditions including diabetes, hypertension, and depression. The catch: reimbursement rates are low enough that "the math only works for organizations that have fully automated most patient interactions," per Pair Team's CEO — making AI not just allowed but operationally required for participating providers.
Pennsylvania filed suit against Character.AI after state investigators interacted with a chatbot named "Emilie" that claimed to be a licensed psychiatrist and produced a fabricated state medical license number while discussing depression treatment. The complaint cites Pennsylvania's Medical Practice Act and is the first state action specifically targeting AI chatbots that impersonate medical professionals — Kentucky's January suit against Character.AI focused on harm to minors, not credentialing fraud. Expect more state attorneys general to follow this template.
On May 4 both frontier labs announced finance-industry-backed enterprise AI services companies. Anthropic revealed a joint venture with Blackstone, Hellman & Friedman, and Goldman Sachs — also backed by Apollo Global Management, Sequoia, GIC, General Atlantic, and Leonard Green — that embeds Applied AI engineers into mid-sized community banks, manufacturers, and regional health systems for Claude integrations. OpenAI's parallel "The Development Company" raised $4 billion at a $10 billion valuation alongside TPG, Brookfield, Advent, and Bain Capital. Both adopt Palantir's forward-deployed engineer model — sending lab engineers into client organizations rather than selling SaaS — a structural signal about how mid-market AI distribution is going to be sold.
A peer-reviewed paper in *Science* pitted OpenAI's o1 reasoning model against two attending physicians on 76 emergency-room triage cases. The model landed on the exact or near-exact diagnosis in 67 percent of cases, versus 55 percent and 50 percent for the two doctors; on a wider 143-case cohort the correct answer sat inside o1's differential 78 percent of the time. The authors caution the inputs were text-only EHR snippets and call for prospective real-world trials before any clinical deployment.
Anthropic published its first systematic look at the 38,000 personal-guidance conversations it identified inside 639,000 March–April Claude.ai chats. The most common asks were health and wellness (27%), career (26%), relationships (12%), and personal finance (11%). Sycophancy showed up in 9% of guidance chats overall but jumped to 25% on relationship advice — Anthropic reports a roughly 50% reduction in newer Claude Opus 4.7 and Mythos Preview training runs.
DeepMind announced an "AI co-clinician" research initiative built on Gemini and Project Astra, structured as a triadic care model where the AI works alongside a supervising physician with a separate "Planner" module monitoring safety boundaries. Academic collaborators include Harvard Medical School and Stanford Medicine, with phased trusted-tester evaluations planned across the US, India, Australia, New Zealand, Singapore, and UAE. It is research, not yet approved for clinical diagnosis or treatment.